Streck Unveils Enhanced ARM-D® Kit for Antimicrobial Resistance

Streck Introduces Updated ARM-D® Kit for Improved Detection

Streck, a leading company in diagnostic solutions, is thrilled to announce the launch of an enhanced version of the ARM-D® Kit, OXA, designed to detect an expanded variety of allelic variants. This new kit identifies 36 additional allelic variants across three newly recognized antimicrobial resistance (AR) gene families. This significant upgrade comes as a direct response to the evolving needs expressed by public health laboratories and aims to provide better oversight of antimicrobial resistance.

Responding to the Needs of Laboratories

The laboratories, particularly those part of the Antimicrobial Resistance Laboratory Network, have increasingly noted the necessity for detection methods capable of identifying diverse gene families and allelic variants. The upgraded Streck ARM-D Kit specifically addresses these needs by including effective detection mechanisms for variants such as OXA-235, OXA-236, and OXA-237 from the OXA-134 family, as well as related beta-lactamase enzymes like OXA-327-like and OXA-198-like.

Commitment to Public Health

Chris Connelly, Streck's director of the Molecular Business Segment, remarked on this enhancement, stating, "We are committed to meeting our customers' needs in public health laboratories. This expanded kit underscores our drive to create tools that aid in better infectious disease testing strategies globally." With this update, Streck aims to further establish itself as a reliable resource for laboratories dedicated to combating antimicrobial resistance.

Comprehensive Detection Capabilities

Streck's ARM-D kits are renowned for their cost-effective and extensive detection abilities, facilitating the identification of over 2,000 allelic variants spanning 25 AR gene families. Results yield a remarkable 100% concordance with whole genome sequencing (WGS) data, marking these kits as crucial pre-WGS screening tools. This capability not only maximizes efficiency but also reduces the expenses associated with AR surveillance efforts in the U.S. and beyond.

Regulatory Information and Usage

It is essential to note that the Streck ARM-D Kit, OXA is designated for research use only and is not cleared for diagnostic procedures. This distinction ensures that the product is utilized appropriately within laboratory settings, underscoring the importance of responsible usage in research applications.

About Streck, Inc.

Founded in 1971, Streck is dedicated to delivering solutions that empower clinical and research laboratories to yield accurate results. The company strives to advance diagnostics, contributing to the enhancement of patient health and well-being across the globe. Manufacturing takes place in La Vista, ensuring that products reach laboratories worldwide, a testament to Streck’s commitment to quality.

Contact Information for Inquiries

For further information regarding the enhancements and capabilities of the ARM-D® Kit, feel free to reach out to Chris Connelly, Director of the Molecular Business Segment, through the provided contact information.

Frequently Asked Questions

What is the ARM-D® Kit, OXA?

The ARM-D® Kit, OXA is a diagnostic tool developed by Streck to detect various allelic variants related to antimicrobial resistance.

How many allelic variants can the kit detect?

The updated kit can now detect over 2,000 allelic variants across 25 gene families.

Is the ARM-D® Kit for general use?

No, the kit is classified for research use only and is not intended for diagnostic procedures.

What makes this kit different from previous versions?

This version includes detection for 36 new allelic variants in three OXA gene families, expanding its overall utility.

Who can benefit from the ARM-D® Kit?

Laboratories engaged in monitoring antimicrobial resistance, especially those in public health, will find this kit particularly beneficial.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.